Betta Pharmaceuticals Co Ltd (300558) - Total Liabilities
Based on the latest financial reports, Betta Pharmaceuticals Co Ltd (300558) has total liabilities worth CN¥3.83 Billion CNY (≈ $559.81 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Betta Pharmaceuticals Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Betta Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300558 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Betta Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Betta Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CRRC Corporation Limited
F:C2L
|
Germany | €333.48 Billion |
|
EXOSENS PROM
PA:EXENS
|
France | €433.30 Million |
|
Great Wall Motor Company Limited
F:GRV
|
Germany | €137.68 Billion |
|
Towne Bank
NASDAQ:TOWN
|
USA | $19.40 Billion |
|
Bank of Hawaii Corporation
NYSE:BOH
|
USA | $22.33 Billion |
|
DOF Group ASA
OL:DOFG
|
Norway | Nkr2.16 Billion |
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
China | CN¥1.98 Billion |
|
Zhejiang Taitan Co Ltd
SHE:003036
|
China | CN¥1.53 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Betta Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Betta Pharmaceuticals Co Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Betta Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Betta Pharmaceuticals Co Ltd (2011–2025)
The table below shows the annual total liabilities of Betta Pharmaceuticals Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.90 Billion ≈ $570.39 Million |
+6.05% |
| 2024-12-31 | CN¥3.68 Billion ≈ $537.85 Million |
-3.16% |
| 2023-12-31 | CN¥3.80 Billion ≈ $555.39 Million |
+28.55% |
| 2022-12-31 | CN¥2.95 Billion ≈ $432.04 Million |
+86.20% |
| 2021-12-31 | CN¥1.59 Billion ≈ $232.03 Million |
+44.66% |
| 2020-12-31 | CN¥1.10 Billion ≈ $160.40 Million |
-34.13% |
| 2019-12-31 | CN¥1.66 Billion ≈ $243.51 Million |
+31.46% |
| 2018-12-31 | CN¥1.27 Billion ≈ $185.24 Million |
+79.18% |
| 2017-12-31 | CN¥706.48 Million ≈ $103.38 Million |
+196.51% |
| 2016-12-31 | CN¥238.27 Million ≈ $34.87 Million |
-5.86% |
| 2015-12-31 | CN¥253.09 Million ≈ $37.04 Million |
+111.09% |
| 2014-12-31 | CN¥119.90 Million ≈ $17.54 Million |
+30.74% |
| 2013-12-31 | CN¥91.71 Million ≈ $13.42 Million |
+3.69% |
| 2012-12-31 | CN¥88.44 Million ≈ $12.94 Million |
-45.68% |
| 2011-12-31 | CN¥162.83 Million ≈ $23.83 Million |
-- |
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma… Read more